Skip to main content
profile image
Selected Works of Robert Sanchez, MD, FACC
Article
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial
Journal of the American College of Cardiology (2020)
  • Deepak L. Bhatt, Brigham and Women's Hospital
  • Andrew H. Briggs, University of London
  • Shelby D. Reed, Duke University
  • Lieven Annemans, Ghent University
  • Michael Szarek, State University of New York System
  • Vera A. Bittner, University of Alabama at Birmingham
  • Rafael Diaz, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina
  • Shaun G. Goodman, University of Alberta
  • Shaun G. Goodman, University of Toronto
  • Robert A. Harrington, Stanford University
  • Keiko Higuchi, Sanofi, Bridgewater, New Jersey
  • Florence Joulain, Sanofi, Chilly-Mazarin, France
  • J. Wouter Jukema, Leiden University Medical Center
  • Qian H. Li, Regeneron, Tarrytown, New York
  • Kenneth W. Mahaffey, Stanford University
  • Robert J. Sanchez, Regeneron, Tarrytown, New York
  • Matthew T. Roe, Verana Health, San Francisco, California
  • Renato D. Lopes, Duke University
  • Harvey D. White, Auckland City Hospital
  • Andreas M. Zeiher, Goethe University Frankfurt
  • Gregory G. Schwartz, University of Colorado Denver
  • Ph. Gabriel Steg, French Institute of Health and Medical Research
  • Ph. Gabriel Steg, National Institutes of Health
  • Pierluigi Tricoci
  • Jay M. Edelberg
  • Corinne Hanotin
  • Guillaume Lecorps
  • Angèle Moryusef
  • Robert Pordy
  • William J. Sasiela
  • Jean-François Tamby
Link
Disciplines
Publication Date
May 12, 2020
DOI
10.1016/J.JACC.2020.03.029
Citation Information
Deepak L. Bhatt, Andrew H. Briggs, Shelby D. Reed, Lieven Annemans, et al.. "Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial" Journal of the American College of Cardiology Vol. 75 Iss. 18 (2020) p. 2297 - 2308
Available at: http://works.bepress.com/robert-sanchez/4/